ATLAS Randomized Clinical Trial:
What Do the Superiority Results Mean for S-ICD Therapy and Sudden Cardiac Death Prevention as a Whole?

Author: Dr Roberto Rordorf
When we challenge evolving medical education, We advance the delivery of patient care.

EDUCARE DIGITAL PLATFORM
A wealth of educational and training content.

- Online training
- Published resources
- In collaboration with experts
- Events and programmes

Register for EDUCARE to discover a valuable portfolio of personalised educational and training opportunities. educare.bostonscientific.eu

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. 2022 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. CRM-1381404-AA
Since 1980, when the first ICD was inserted in a patient, ICDs have evolved to become the mainstay therapy for both primary and secondary prevention of all-cause cardiac mortality in patients at risk of dying because of fatal cardiac arrhythmias. However, the risks of complications, in particular those related to lead failure and systemic infections, associated with traditional transvenous (TV-ICD) devices are an ongoing concern. The subcutaneous ICD (S-ICD) was designed to overcome these intravascular complications by its entirely extrathoracic implantation. Over the past couple of decades, studies have focused on addressing the efficacy and safety of S-ICDs compared with TV-ICDs and have demonstrated the proven performance of S-ICDs.

The PRAETORIAN trial was the first head-to-head randomised controlled trial to compare S-ICDs with TV-ICDs. The trial randomised 849 eligible patients from clinical centres across the US and Europe between March 2011 and January 2017. Patient diagnoses at baseline are shown in Table 1.

PRAETORIAN demonstrated that the S-ICD was not inferior to the TV-ICD regarding the composite endpoint (device-related complications or inappropriate shocks) at 4 years. More recently, the first randomised superiority trial has been performed. The ATLAS trial was presented as a late-breaking clinical trial at the 2022 Heart Rhythm Society Cardiology Conference. It demonstrated 92% fewer serious lead-related complications for S-ICDs compared with TV-ICDs at 6 months following implantation. This evidence indicates that the S-ICD could be an appropriate choice of device for patients without the need for pacing, particularly those considered to be at a higher risk of lead-related complications.

Accordingly, the purpose of this review is to empower both clinical cardiologists and those who implant ICDs with an up-to-date review of the key clinical evidence comparing S-ICDs and TV-ICDs in order to help inform their patient selection.

Clinical Evidence
PRAETORIAN
PRAETORIAN was a RCT in which the primary endpoint was a composite of device-related complications and inappropriate shocks. The trial randomised 849 eligible patients from clinical centres across the US and Europe between March 2011 and January 2017. Patient diagnoses at baseline are shown in Table 1.

PRAETORIAN demonstrated that the S-ICD was not inferior to the TV-ICD regarding the composite endpoint (device-related complications and inappropriate shocks) at 4 years (Figure 1).
### Table 1: Summary of Study Characteristics

| Study                  | Design                          | Patients (n) | Patient Baseline Characteristics | Primary Outcome(s)                                                                 | Results                                                                                                                                                                                                 | Key Findings                                                                                     |
|------------------------|---------------------------------|--------------|----------------------------------|------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| PRAETORIAN<sup>3</sup> (NCT01296022) | Non-inferiority RCT              | 849          | ≥18 years; Class I or Ia indication for ICD therapy for primary or secondary prevention; Ischaemic cardiomyopathy, S-ICD: 67.8%; TV-SCD: 70.4%; Non-ischaemic cardiomyopathy, S-ICD: 23.2%; TV-SCD: 23.2%; Genetic arrhythmia syndrome, S-ICD: 4.7%; TV-SCD: 4.3%; Hypertrophic cardiomyopathy, S-ICD: 3.5%; TV-SCD: 17%; Idiopathic VF, S-ICD: 2.6%; TV-SCD: 1.2%; Congenital heart disease, S-ICD: 0.7%; TV-SCD: 0.7%; Other | Composite of device-related complications and IAS                                                                                           | At median follow-up of 49.1 months, a primary endpoint event occurred in 68 patients in the S-ICD group and 68 patients in the TV-ICD group. S-ICD was non-inferior to the TV-ICD regarding device-related complications and IAS in patients with an indication for an ICD but no indication for pacing |                                                                                                 |
| UNTOUCHED<sup>5</sup> (NCT02433379) | Multi-national, prospective, non-randomised study | 1,111        | Primary prevention patients with an LVEF ≤35% undergoing a *de novo* S-ICD implant procedure; 53.5% ischaemic heart disease; 87.7% symptomatic heart failure and a mean LVEF 26.4 ± 5.8% | IAS-free rate at 540 days (18 months) compared to a performance goal of 91.6% | 95.9% IAS-free rate at 18 months                                                                                                                                                                           | S-ICD offers high efficacy and safety                                                                                               |
| EFFORTLESS<sup>4</sup> (NCT01085435) | An international, observational, non-randomised, standard of care registry | 994          | 29% ischaemic cardiomyopathy; 18% dilated cardiomyopathy; 20% channelopathies; 65% primary prevention indication | S-ICD complication rate 30 days post-implantation; S-ICD complication rate at 360 days; Percentage of IAS for AF or SVT | S-ICD complication-free rate was 99.9% at 30 days, 98.5% at 360 days, and 94.5% after 5 years; IAS rates at 1 and 5 years were 8.7% and 16.9%, respectively | The S-ICD maintains a high level of shock efficacy over time                                                                        |
| Rordorf et al. 2021 (meta-analysis) | Meta-analysis of primary studies that directly compare clinical outcomes and complications between S-ICD and TV-ICD | 9,073 (13 studies) | Mean LVEF was 40 ± 10%; 30% of patients were female; 73% had an ICD implanted for primary prevention | The composite of clinically relevant complications and IAS | No statistically significant difference in the risk of the primary outcome between S-ICD and TV-ICD; S-ICD was at least as effective and safe for prevention of SCD in patients without the need for pacing for TV-ICD regarding serious lead-related complications |                                                                                                 |
| ATLAS<sup>6</sup> (NCT02881255) | Prospective RCT                 | 503          | Aged ≥18 to 60 years, standard indication for ICD; Aged ≥18 years and one of the following: inherited arrhythmia syndrome, a prior pacemaker or ICD removal for infection; need for hemodialysis, prior heart valve surgery or chronic obstructive pulmonary disease (with FEV<sub>1</sub> < 1.5 l) | Reduction in the rate of major lead-related complications at 6 months post-implant | S-ICD reduces the rate of major, lead-related complications by 92%                                                                                                                                 | S-ICD is superior to TV-ICD regarding serious lead-related complications                                                                 |

IAS = inappropriate shock; LVEF = left ventricular ejection fraction; RCT = randomised controlled trial; S-ICD = subcutaneous ICD; SVT = supraventricular tachycardia; TV-ICD = transvenous ICD

In a secondary analysis of PRAETORIAN, appropriate therapy was evaluated along with assessment of whether anti-tachycardia pacing (ATP) reduces the number of inappropriate shocks. It found no statistical difference in the number of patients treated with appropriate ICD therapy in the S-ICD and TV-ICD groups, and patients with an S-ICD were more likely to receive an appropriate shock. However, the overall number of appropriate shocks was comparable between the two groups, despite the inability of the S-ICD to deliver ATP.<sup>7</sup>

**UNTOUCHED**

UNTOUCHED was a multinational, prospective, non-randomised study designed to evaluate the rate of inappropriate shocks.<sup>5</sup> It included a more typical, contemporary ICD patient population (i.e. patients with LVEF ≤35%) implanted with an S-ICD compared with the patient populations of previous S-ICD studies. The primary endpoint was the inappropriate shock-free rate at 540 days (18 months) compared to a performance goal of 91.6%, derived from the results obtained with optimally programmed TV-ICD patients in the MADIT-RIT study.<sup>8</sup> The trial spanned almost 3 years and took place across 110 sites located in the US, Canada and Europe between June 2015 and February 2018. UNTOUCHED enrolled 1,111 patients with LVEF ≤35% (ischaemic or non-ischaemic heart disease) who were eligible for S-ICD therapy.

Overall, at 18 months the inappropriate shock-free rate was 95.9% with a lower confidence limit of 94.8%, meeting the performance goal of 91.6%. The inappropriate shock-free time course is presented in Figure 2.

UNTOUCHED demonstrated that the inappropriate shock rates of S-ICDs,
in a cohort of patients with more comorbidities and lower LVEFs than previous S-ICD studies, are comparable to those observed in previous studies with TV-ICDs. It should be noted that the 1-year inappropriate shock rates measured across S-ICD studies have decreased substantially over time because of the implementation of conditional zone programming and technology improvements to minimise T wave oversensing, including the SMART Pass filter (Boston Scientific) that was specially designed to reduce cardiac oversensing.

EFFORTLESS

The EFFORTLESS S-ICD registry was a non-randomised, standard of care, multicentre registry set up to collect long-term system-related, clinical, and patient reported outcome data from patients implanted with S-ICDs.4 It is the largest study of long-term outcomes associated with the S-ICD. Study endpoints were the perioperative (30 days post implantation) S-ICD complication rate, 360-day S-ICD complication rate and the incidence of inappropriate shocks for AF or supraventricular tachycardia (SVT). The registry enrolled 994 patients with a diverse range of cardiac disease at 46 centres in 11 countries from February 2011 to November 2014. The 5-year outcomes were also reported, including spontaneous shock efficacy.

The results from EFFORTLESS showed an S-ICD complication-free rate of 99.9% at 30 days, 98.5% at 360 days and 94.5% after 5 years (Figure 3).

In this long-term S-ICD registry, the majority of complications occurred in the first few months post implant, with the most common complication being infection requiring replacement. Erosion was the second most common complication, occurring more commonly in years 2–5. Moreover, EFFORTLESS provided valuable clinical evidence of the long-term efficacy of the S-ICD, demonstrating consistently high spontaneous shock efficacy (98%) over an average of 5 years of follow-up. This result is consistent with those of other TV-ICD studies.7–12

Meta-analysis

In a meta-analysis of the available clinical studies comparing S-ICD and TV-ICD, the primary outcome was the composite of all relevant complications and inappropriate shocks.2 The analysis included 13 studies and a total of 9,073 patients. Patient baseline characteristics were comparable between those implanted with S-ICD (3,433 patients) and those with TV-ICD (5,640 patients). Mean LVEF was 40% ± 10%. Underlying cardiopathies were an ischaemic aetiology (46% of patients), non-ischemic cardiomyopathy (44% of patients) and channelopathy (9% of patients).

The risk of the composite of relevant complications and inappropriate shocks between S-ICD and TV-ICD patients was not statistically significant different. There was also no statistically significant difference between S-ICD and TV-ICD patients for the global risk of inappropriate shock (Figure 4). However, patients implanted with an S-ICD had a lower risk of lead complications than TV-ICD patients (Figure 5). Furthermore, patients implanted with an S-ICD had a lower risk of inappropriate shocks due to SVT but a higher risk of inappropriate shocks for cardiac oversensing.

Finally, the risk of appropriate shocks was similar in S-ICDs versus TV-ICDs and major clinical endpoints, such as cardiovascular and non-cardiovascular death, were comparable among the two groups.

This meta-analysis – the largest of its kind – compared clinical outcomes and complications between patients implanted with S-ICDs versus TV-ICDs in those with an indication for an ICD without the need for pacing. It revealed that the overall risk of clinically relevant complications and inappropriate

---

**Figure 1: Time-to-first-event Curves for the Primary Endpoint and Its Components in the PRAETERIOR Study**

| Endpoint                  | S-ICD | TV-ICD |
|---------------------------|-------|--------|
| A: Primary composite endpoint (device-related complications or inappropriate shocks) | HR 0.99 (95% CI [0.71–1.39]) | p=0.01 for noninferiority |
| B: Device-related complications | HR 0.69 (95% CI [0.44–1.09]) | |
| C: Inappropriate shocks | HR 1.43 (95% CI [0.89–2.30]) | |

A: Primary composite endpoint (device-related complications or inappropriate shocks); B: Device-related complications; C: Inappropriate shocks. S-ICD = subcutaneous ICD; TV-ICD = transvenous ICD. Source: Knops et al. 2020.1 Reproduced with permission from Massachusetts Medical Society.
**ATLAS: What do the Superiority Results Mean for S-ICD Therapy?**

**Figure 2: Inappropriate Shock-free Rate in the UNTOUCHED Study**

![Kaplan-Meier curve illustrating the primary endpoint result (IAS-free rate at 18 months) in the UNTOUCHED study. IAS = inappropriate shock. LCL = lower confidence limit. Source: Gold et al. 2020. Reproduced with permissions from Wolters Kluwer Health, Inc.](image1)

**Figure 3: Complication-free Rates With Subcutaneous ICD Use in the EFFORTLESS Study**

![K-M curve of complication-free rates for overall complications (Types I–III) and complications caused by the S-ICD system (Type II) in the EFFORTLESS study. K–M = Kaplan–Meier; S-ICD = subcutaneous ICD. Source: Lombaase et al. 2022. Reproduced with permissions from Oxford University Press.](image2)

Shocks was not different between two patient groups. The results also showed that S-ICDs and TV-ICDs are associated with different types of complications and different prevalent causes of inappropriate shocks. This should be taken into consideration by clinicians implanting the device when selecting the most appropriate choice of ICD for their patient.

**ATLAS**

ATLAS was a prospective, randomised controlled head-to-head trial. The primary outcome was the rate of lead-related complications of S-ICD compared to TV-ICD measured at 6 months following implant. The study enrolled 503 patients with a primary or secondary standard indication for an ICD or with inherited cardiac arrhythmias or with cardiac conditions considered at increased risk for lead-related complications. It took place across 14 clinical centres in Canada. Patient diagnoses at baseline are shown in Table 1.

Serious lead-related complications occurred in 4.8% of patients with a TV-ICD versus 0.4% of those with an S-ICD at 6 months. This demonstrates that the S-ICD is superior to TV-ICD, achieving 92% fewer serious lead-related complications. Serious complications were defined as moderate-severe or severe tricuspid regurgitation, haemothorax/pneumothorax, cardiac perforation, tamponade, pericardial effusion or pericarditis, ipsilateral upper-extremity deep vein thrombosis and lead dislodgement or loss of sensing or pacing requiring revision.

ICD effectiveness, defined as the rate of failed first ICD shock, was similar between S-ICDs and TV-ICDs. The rate of inappropriate shocks showed a trend toward a higher risk with S-ICDs versus TV-ICDs (6.4 versus 2.8%), although the difference was not statistically significant.

**Author Expertise**

Dr Roberto Rordorf, cardiologist and electrophysiologist, is the Head of the Arrhythmias and Electrophysiology Unit at the Policlinico San Matteo Foundation in Pavia, Italy. The Arrhythmias Unit has had considerable experience over the past few decades in the field of device therapy for patients with heart failure and cardiac arrhythmias. Pavia is one of the few centres in Italy that participated in the design and conduct of one of the pivotal trials on cardiac resynchronisation therapy, the CARE-HF study. It was also one of the first centres worldwide to test vagal stimulation in the treatment of chronic heart failure. As a leading national centre in the treatment of patients with heart failure, cardiomyopathies and channelopathies, significant clinical and research activity on ICD therapy is conducted there. Furthermore, patients with complex atrial and ventricular arrhythmias are treated by means of catheter ablation on a regular basis. Beyond the percutaneous treatment of cardiac arrhythmias, Pavia is one of the few centres worldwide with recognised long-term experience in the neuromodulation of cardiac arrhythmias.

**Discussion**

As ICD technology progresses and programming algorithms improve, ICD therapy has evolved dramatically and today it has become the cornerstone of treatment for both primary and secondary prevention of patients at risk of sudden cardiac death. In addition, advancing age and increased comorbidities are forever putting forward more candidates for intervention. The safety and efficacy of the S-ICD have been demonstrated in several studies over the past couple of decades. While traditional TV-ICDs continue to bring risks of lead complications, the latest data from the ATLAS trial now further expand the findings from PRAETORIAN and other studies by demonstrating that the S-ICD is superior to the TV-ICD in preventing the serious complications associated with transvenous leads as early as 6 months after implant.

**Who Should Receive the Subcutaneous-ICD?**

Evidence from clinical trials shows that S-ICDs are appropriate for a broad range of patient populations. A recent study on a large representative national cohort of older patients supported the use of
S-ICD in patients aged >55 years who were at risk of sudden cardiac death. The safety and efficacy of S-ICD in teenagers and young adults has also been demonstrated in a large, real-world cohort of S-ICD patients stratified by age at implantation. The rates of inappropriate shocks and complications were not different in younger versus older patients. Historically, young patients have often represented the most suitable candidates for an entirely S-ICD system because they face a lifetime of device therapy and rarely have a pre-existing or concurrent pacing or cardiac resynchronisation therapy indication. It should also be taken into consideration that, even in a patient implanted with an S-ICD who has a lead complication or a device infection, lead extraction is likely to be more straightforward and less risky with the S-ICD than with the TV-ICD.

The data show that S-ICD use avoids many of the serious complications associated with invasive leads, including serious infection and lead-related complications. Further, the superiority of S-ICD occurs 6 months after implant in adults of all ages with the most common ICD indications. Patients experiencing transvenous lead complications can also be very good candidates for S-ICD implantation, either where a transvenous lead abandonment strategy is adopted or following percutaneous lead extraction.

ATLAS: What do the Superiority Results Mean for S-ICD Therapy?

Figure 4: Meta-analysis Findings for Inappropriate Shock

| Study or Subgroup | S-ICD Events | TV-ICD Events | Weight | OR M-H, Random [95% CI] | OR |
|-------------------|--------------|--------------|--------|-------------------------|----|
| 3.7.1 Adult       |              |              |        |                         |    |
| Boveda, 2018      | 0            | 31           | 0      | 0.31                     |    |
| Brouwer, 2016     | 17           | 17           | 0.45   | 0.05 [0.01–0.40]         |    |
| Friedman, 2016    | 3            | 1920         | 0.25   | 0.05 [0.01–0.40]         |    |
| Honarbaksh, 2017 | 2            | 3840         | 0.05   | 0.05 [0.01–0.40]         |    |
| Kobe, 2013        | 6            | 69           | 0.25   | 0.05 [0.01–0.40]         |    |
| Liang, 2019       | 3            | 3            | 0.25   | 0.05 [0.01–0.40]         |    |
| Petit, 2013       | 0            | 9            | 0.25   | 0.05 [0.01–0.40]         |    |
| Quast, 2018       | 1            | 391          | 0.05   | 0.05 [0.01–0.40]         |    |
| Viani, 2019       | 0            | 90           | 0.05   | 0.05 [0.01–0.40]         |    |
| Total (95% CI)    |              |              | 1.09   | 0.73–1.64                |    |
| Heterogeneity: Tau² = 0.00, Chi² = 9.62, df = 8 (p=0.02); I² = 0% |
| Test for overall effect: Z = 1.44 (p=0.15) |
| Total events | 96 | 71 |

Figure 5: Meta-analysis Findings for Lead-related Complications

| Study or Subgroup | S-ICD Events | TV-ICD Events | Weight | OR M-H, Random [95% CI] | OR |
|-------------------|--------------|--------------|--------|-------------------------|----|
| Boveda, 2018      | 0            | 31           | 0      | 0.31                     |    |
| Brouwer, 2016     | 17           | 17           | 0.45   | 0.05 [0.01–0.40]         |    |
| Friedman, 2016    | 3            | 1920         | 0.25   | 0.05 [0.01–0.40]         |    |
| Honarbaksh, 2017 | 2            | 3840         | 0.05   | 0.05 [0.01–0.40]         |    |
| Kobe, 2013        | 6            | 69           | 0.25   | 0.05 [0.01–0.40]         |    |
| Liang, 2019       | 3            | 3            | 0.25   | 0.05 [0.01–0.40]         |    |
| Petit, 2013       | 0            | 9            | 0.25   | 0.05 [0.01–0.40]         |    |
| Quast, 2018       | 1            | 391          | 0.05   | 0.05 [0.01–0.40]         |    |
| Viani, 2019       | 0            | 90           | 0.05   | 0.05 [0.01–0.40]         |    |
| Total (95% CI)    | 2,840        | 4,819        | 1.00   | 0.96–0.92                |    |
| Heterogeneity: Tau² = 0.00, Chi² = 9.62, df = 8 (p=0.03); I² = 0% |
| Test for overall effect: Z = 5.08 (p=0.00001) |
| Total events | 5 | 70 |
strategy. Furthermore, we have recently demonstrated positive patient acceptance of the S-ICD, even in groups at risk of psychological distress, such as females or those with a smaller body habitus, independent of the generator positioning.20

Patients with inherited cardiac arrhythmias and cardiomyopathies are usually younger and could be considered suitable for S-ICD therapy. Nevertheless, data from the literature in these scenarios are still scarce and debatable.

Regarding channelopathies, most available data are available for Brugada syndrome. Brugada patients are usually young and active with a long life expectancy, only rarely requiring pacing. Accordingly, although data with longer follow-up periods are needed, Brugada patients have been considered to be the ideal candidates for S-ICDs in many centres. Previous studies have demonstrated that the S-ICD is effective and associated with an acceptable rate of complications in patients with channelopathies.21,24 Nevertheless, a recent study raised a potential eligibility limitation with the use of S-ICD in Brugada patients, with the authors demonstrating a screening pass rate of 85% at rest and only 70% when a type 1 Brugada ECG pattern was induced by means of the ajmaline test.21

Patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) and hypertrophic cardiomyopathy (HCM) are usually young and active and therefore also potentially good candidates for the S-ICD. S-ICDs have been proven to be highly effective in terminating both spontaneous and induced arrhythmias in ARVC.26 Moreover, although the rate of ARVC patients that experienced inappropriate shocks was not negligible (14% at 1 year), it was in line with data from previous reports on TV-ICD (10–25%).27–29 In a large cohort of patients with HCM, the S-ICD was associated with a lower incidence of overall device therapies when compared to the TV-ICD. The difference was mainly driven by a significantly higher ATP therapy rate in the TV-ICD group, suggesting that ATP therapy is very likely to be unnecessary in HCM patients.30

Some aspects of the S-ICD system hold me back from proposing the S-ICD as the first choice in every patient in the need of an ICD. These include the need for conscious sedation or, in some cases, even the support of an anesthesiologist during the implantation procedure, along with the relatively shorter battery life of 7–9 years and the larger size of the S-ICD compared with the TV-ICD. However, these relate to technical issues associated with any young technology and will undoubtedly be resolved with on-going developments. Indeed, the system has already evolved significantly from its original version, especially with the arrhythmia detection algorithms that have allowed a substantial reduction in inappropriate shocks, as demonstrated in the UNTOUCHEd study.5 Moreover, it must be recognised that, despite the initial concern about the size of the current S-ICD, patient acceptance is positive and its use is sometimes associated with better positive appraisal in comparison with the TV-ICD.72

Conclusion

Based on the current evidence presented so far, further strengthened by the results of the latest PRAETORIAN and ATLAS trials, I strongly believe that the use of the S-ICD for patients across all ages and with a wide range of indications who don’t require pacing should be significantly broadened in everyday clinical practice. S-ICDs are particularly appropriate for young and active patients, and all those patients deemed at higher risk of infections and lead complications should be screened for the S-ICD as first-line therapy. With appropriate patient selection alongside modern device programming, S-ICDs can be chosen with confidence in order to reduce the rate of complications in our patients who are at risk of sudden cardiac death.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.lfu-bsci.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. 2022 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. CRM-1319702-AA CE 2797.

1. Koneru JN, Jones PW, Hammil EF, et al. Risk factors and temporal trends of complications associated with transvenous implantable cardiac defibrillator leads. J Am Heart Assoc 2018;7:e007691. https://doi.org/10.1161/ JAH017.007691. PMID: 29748177.
2. Rordorf R, Cássula M, Pezza L, et al. Subcutaneous versus transvenous implantable defibrillator: an updated meta-analysis. Heart Rhythm 2021;18:382–91. https://doi.org/10.1016/j.hrthm.2020.11.013. PMID: 33212250.
3. Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med 2020;383:532–36. https://doi.org/10.1056/ NEJMoa195532. PMID: 32757521.
4. Lambiase PD, Thoens DE, Murgatroyd F, et al. Subcutaneous implantable cardioverter defibrillators: long-term results of the EFFORTLESS study. Eur Heart J 2022;43:2037–50. https://doi.org/10.1093/eurheartj/ eeha521. PMID: 35900907.
5. Gold MR, Lambiase PD, Bi-Chami MF, et al. Primary results from the understanding outcomes with the S-ICD in primary prevention patients with low ejection fraction (UNTOUCHEd) trial. Circulation 2021;143:7–17. https://doi.org/10.1161/CIRCULATIONAHA.120.048728. PMID: 33070364.
6. Healey JS, Mohnike MK, Bashir J, et al. LB-733-01: Multicenter automatic defibrillator implantation trial: reduce inappropriate therapy MADIT-RIT. background, rationale, and clinical protocol. Ann Noninvasive Electrocardiol 2012;17:176–85. https://doi.org/10.1111/j.1542-4744.2012.00531.x. PMID: 22965336.
7. Healey JS, Hofmiesler SH, Glikson M, et al. Cardioverter defibrillator implantation without induction of ventricular fibrillation: A single-blind, non-inferiority, randomised controlled trial (SMIELD). Lancet 2015;385:785–91. https://doi.org/10.1016/S0140-6736(15)30363-6. PMID: 25755919.
8. Blatt JA, Poole JE, Johnson GW, et al. No benefit from defibrillation threshold testing in the S-ICD-HeFT (pulmonary cardiac death in heart failure trial). J Am Coll Cardiol 2008;52:551–6. https://doi.org/10.1016/j.jacc.2008.04.051. PMID: 18607240.
9. Kutyla V, Huth Ruisdal AC, Ahtas MK, et al. Clinical impact, safety, and efficacy of s- versus dual-coil ICD leads in MADIT-CRT. J Cardiovasc Electrophysiol 2013;24:246–52. https://doi.org/10.1111/jce.12279. PMID: 23888963.
10. Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary prevention defibrillator patients: results from the Pacing Fat VT Reductions Shock Therapies (PainFREE Rx II) trial. Circulation 2013;117:2895–8. https://doi.org/10.1161/ CIRCULATIONAHA.113.256263. PMID: 15972965.
11. Celisland JG, Daubert JC, Endmann E, et al. The CARE-HF study (Cardiac Resynchronization in Heart Failure study rationale, design and end-points). Eur Heart J 2001;22:3481–9. https://doi.org/10.1053/NEJMoa0050496. PMID: 15753115.
12. Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur Heart J 2008;29:864–91. https://doi.org/10.1093/eurheartj/ehn106. PMID: 18766688.
13. Savastano S, Dusi V, Bardi E, et al. Anatomical-based percutaneous left stellate ganglion block in patients with drug refractory electrical storm and structural heart disease: a single-centre case series. Europace 2021;23:581–6. https://doi.org/10.1093/europace/euaa359. PMID: 33900159.
14. Dusi V, Pugliese L, De Ferranti GM, et al. Left cardiac sympathetic denervation for long QT syndrome: 50 years’ experience provides guidance for management. JACC Clin Electrophysiol 2022;8:281–94. https://doi.org/10.1016/j.jenceph.2021.09.002. PMID: 35339422.
15. Friedman DJ, Qin L, Parzynski C, et al. Longitudinal outcomes of subcutaneous or transvenous implantable cardioverter-defibrillators in older patients. J Am Coll Cardiol 2022;79:1050–9. https://doi.org/10.1016/j.jacc.2021.12.033. PMID: 35300816.
16. Guilleta S, Gaspertetti A, Schiavone M, et al. Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter defibrillators: a propensity-matched analysis from a multicenter European registry. Heart Rhythm 2022;19:1109–15. https://doi.org/10.1016/j.hrthm.2020.02.029. PMID: 35257974.
17. Behar N, Galand V, Martins RP, et al. Subcutaneous implantable cardioverter-defibrillator lead extraction. First multicenter French experience. JACC Clin Electrophysiol 2020;6:683–70. https://doi.org/10.1016/j.jceh.2020.04.012. PMID: 32703570.
18. vani S, Migliore F, Tola G, et al. Use and outcomes of subcutaneous ICD after transvenous ICD extraction: an
21 Russo V, Viani S, Migliore F, et al. Lead abandonment and subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation in a cohort of patients with ICD lead malfunction. *Front Cardiovasc Med* 2021;8:18. https://doi.org/10.3389/fcvm.2021.692943; PMID: 34395560.

22 Vicentini A, Bisogni G, De Vivo SM, et al. Patient acceptance of subcutaneous versus transvenous defibrillator systems: a multi-center experience. *J Cardiovasc Electrophysiol* 2022;33:81–9. https://doi.org/10.1111/jce.15297; PMID: 34707012.

23 Kuschyk J, Müller-Leisse J, Duncker D, et al. Comparison of transvenous vs subcutaneous defibrillator therapy in patients with cardiac arrhythmia syndromes and genetic cardiomyopathies. *Int J Cardiol* 2021;323:100–5. https://doi.org/10.1016/j.ijcard.2020.08.041; PMID: 32871189.

24 Lambiase PD, Eckardt L, Theuns DA, et al. Evaluation of subcutaneous implantable cardioverter-defibrillator performance in patients with ion channelopathies from the EFFORTLESS cohort and comparison with a meta-analysis of transvenous ICD outcomes. *Heart Rhythm* 2020;17:126–35. https://doi.org/10.1016/j.hrthm.2020.10.002; PMID: 3413890.

25 Conte G, Cattaneo F, de Asmundis C, et al. Impact of SMART Pass filter in patients with ajmaline-induced Brugada syndrome and subcutaneous implantable cardioverter-defibrillator eligibility failure: results from a prospective multicentre study. *Eur Heart J* 2022;43:845–54. https://doi.org/10.1093/eurheartj/ehac413; PMID: 34499723.

26 Migliore F, Viani S, Bongiorni MG, et al. Subcutaneous implantable cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy: results from an Italian multicenter registry. *Int J Cardiovasc Imaging* 2019;25:74–8. https://doi.org/10.1007/s10554-019-01456-w.

27 Corrado DC, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. *Circulation* 2015;132:441–53. https://doi.org/10.1161/CIRCULATIONAHA.115.017944; PMID: 26216213.

28 Olde Nordkamp LR, Wilde AA, Tjostrøen JS, et al. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention. *Circ Arrhythm Electrophysiol* 2013;6:91–100. https://doi.org/10.1161/CIRCEP.112.975268; PMID: 23275262.

29 Link MS, Wang PJ, Hough CJ, et al. Arrhythmogenic right ventricular dysplasia: clinical results with implantable cardioverter defibrillators. *J Interv Card Electrophysiol* 2019;1:75–84. https://doi.org/10.1007/s10841-018-0716-0; PMID: 31983570.
Reasons to believe in S-ICD

• Over 100,000 patients protected¹
• Almost 2 decades of clinical evidence²,³,⁴
• Reducing risks by design⁵

References:
1. BSC Data on file
2. Bardy GH, Smith WM, Hood MA et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363:36-44 (78 patients; Sept. 2001-Feb. 2004)
3. Al-Khatib SM, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018; 15(10): e190-e252.
4. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015 Nov 1;36(41):2793-2867. doi: 10.1093/eurheartj/ehv316. Epub 2015 Aug 29. PMID: 26320106.
5. Knops RE, et al. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med. 2020 Aug 6;383(6):526-536.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. 2022 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. CRM-1319702-AA CE 2797.